newsfilter
← Latest News
GlobeNewswire·

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant